{"id":"https://genegraph.clinicalgenome.org/r/ae433ec8-2bf9-4bb1-9c69-c8ba6ba66a97v1.0","type":"EvidenceStrengthAssertion","dc:description":"The FOXC1 gene was first reported in relation to anterior segment dysgenesis in 1998 (PMID: 9620769). The specific disease entity, anterior segment dysgenesis 3, is one of eight such conditions distinguished by a single monogenic cause. Onset of symptoms is variable, and affected patients can be diagnosed in infancy or as late as in adulthood. Findings are primarily ocular and localized to the anterior segment, and frequently include prominent and anteriorly displaced Schwalbeâ€™s line, iris hypoplasia, ectopia pupillae, abnormal pupil shape and iridocorneal adhesions. Glaucoma is a well-characterized phenotype that develops with approximately 50-75% penetrance, while corneal neovascularization and Peters anomaly have been observed in some affected individuals. Some affected patients exhibit additional extraocular symptoms, and are not typically diagnosed with anterior segment dysgenesis 3, but rather with Axenfeld-Rieger syndrome 3. Extraocular symptoms can include hypertelorism, midface retrusion, maxillary hypoplasia, microdontia, hearing loss, protuberant umbilical skin, heart anomalies, mild cerebellar vermis hypoplasia, and dilated perivascular spaces. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, the molecular mechanism (monoallelic loss of function) and mode of inheritance (autosomal dominant) were found to be consistent among patients with anterior segment dysgenesis 3 and Axenfeld-Rieger syndrome 3, while the phenotypic variability between them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, cases caused by inherited FOXC1 variants have been lumped into a single disease entity, referred to as anterior segment dysgenesis 3 (MONDO:0024456, OMIM #601631). Ten suspected pathogenic variants were scored as part of this curation (one nonsense, three frameshift, and six missense affecting the Forkhead domain of the encoded protein), which have been collectively reported in ten probands in five publications (PMID: 9620769, PMID: 9792859, PMID: 10713890, PMID: 17210863, PMID: 11170889). More case-level evidence is available in the literature (PMID: 11170889, PMID: 16936096), but its inclusion in this curation was not necessary to reach the maximum score for genetic evidence (12 points). It is important to note that a subset of affected patients exhibit either loss or gain of FOXC1 copy number, highlighting the importance of precise FOXC1 gene dosage in anterior segment development (PMID: 11170889). Patients harboring duplications in FOXC1 exhibit a particularly severe prognosis for the development of glaucoma relative to patients with other types of FOXC1 variants (PMID: 17197537). However, these probands were not scored as part of this curation. While FOXC1 variants and copy number alterations are estimated to be present in approximately 24% of patients with anterior segment dysgenesis (PMID: 20881294), the high GC content of the locus causes sequencing challenges that may lead to under-identification of FOXC1 variants by next-generation sequencing-based panels. This gene-disease relationship has not been studied in case-control studies at the single variant level or aggregate variant level. The mechanism of pathogenicity appears to be monoallelic loss of function, characterized in some cases by truncation of the majority of the protein product and in other cases by missense variants affecting the Forkhead domain that trigger defects in DNA binding, transactivation, and/or nuclear localization (PMID: 11179011). All probands scored in this curation harbored one variant allele within the FOXC1 locus. This gene-disease association is also supported by biochemical evidence that FOXC1 functions as a transcription factor to coordinate normal development of the ocular anterior segment (PMID: 11782474, PMID: 17993506) and to promote the survival of trabecular meshwork cells (PMID: 24556684), which are known to regulate intraocular pressure and exhibit reduced cellularity in glaucoma. FOXC1 physically interacts with and colocalizes with PITX2, another transcription factor associated with anterior segment dysgenesis through an autosomal dominant mode of inheritance (PMID: 16449236). This interaction may explain why FOXC1 variants and PITX2 variants appear to act as modifiers of Axenfeld-Rieger syndrome severity when present in the same family (PMID: 21837767). FOXC1 missense variants exogenously expressed in non-patient cells exhibit disruption of nuclear localization or DNA binding in some cases, and reduced transactivation of a reporter gene in all cases (PMID: 14506133). Phenotypes of affected human patients are recapitulated by various model organisms with FOXC1 loss-of-function, including abnormalities in ocular morphology and vascularization in both zebrafish (PMID: 19458328, PMID: 32720677) and mice (PMID: 22171010). A heterozygous knockout mouse model also exhibited ectopia pupillae, irido-corneal attachments, hypoplastic iris stroma, and trabecular meshwork abnormalities (PMID: 10767326). In summary, FOXC1 is definitively associated with anterior segment dysgenesis 3. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on November 18, 2021 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/ae433ec8-2bf9-4bb1-9c69-c8ba6ba66a97","GCISnapshot":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2021-12-15T03:13:03.559Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2021-12-15T03:12:46.818Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59847601-c8b7-4b29-a8f5-ec9e450611aa","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.67C>T (p.Gln23Ter) is a nonsense variant predicted to disrupt approximately 96% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59847601-c8b7-4b29-a8f5-ec9e450611aa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10713890","allele":{"id":"https://genegraph.clinicalgenome.org/r/e870de00-c556-4b27-9f89-c6a85480853f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.67C>T (p.Gln23Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119637"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a5698686-00df-4fb9-807b-1d91ad092a36","type":"EvidenceLine","dc:description":"This variant has a dramatic defect in transactivation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a5698686-00df-4fb9-807b-1d91ad092a36_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001453.3(FOXC1):c.392C>T (p.Ser131Leu) is a missense variant that exhibits a dramatic (>20X) reduction in binding to its canonical DNA binding site in vitro (PMID: 11179011, Fig. 5A) and no ability to bind to oligonucleotides designed to mimic FOXC1 binding sites (PMID: 11179011, Figs. 6B and 6C). Activation of a luciferase reporter construct was reduced to 7.4% (PMID: 11179011, Fig. 7).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a5698686-00df-4fb9-807b-1d91ad092a36_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","allele":{"id":"https://genegraph.clinicalgenome.org/r/3215737e-3665-4f0a-8116-8f0cbdc82c82","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.392C>T (p.Ser131Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119632"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/23f311b1-59f4-487b-a0d0-814afe6b37b6","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.264dup (p.Met89HisfsTer217) is a frameshift variant predicted to disrupt approximately 84% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23f311b1-59f4-487b-a0d0-814afe6b37b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11170889","allele":{"id":"https://genegraph.clinicalgenome.org/r/f96beaed-5089-4252-ada3-a0a86cc15a08","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.264dup (p.Met89HisfsTer217)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497029025"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/db639c70-0c70-4560-b981-2ae664a26e14","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.99_108del (p.Gly34ThrfsTer8) is a frameshift variant in the only exon of FOXC1, and is predicted to disrupt approximately 94% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db639c70-0c70-4560-b981-2ae664a26e14_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9792859","allele":{"id":"https://genegraph.clinicalgenome.org/r/1fb7149d-6015-459a-baec-ba4f97c0a60b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.99_108del (p.Gly34ThrfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1147243049"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/62beeb2e-75b9-448a-b021-af85c8a27d9d","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.378C>G (p.Ile126Met) is a missense variant located within the forkhead (DNA-binding) domain, which harbors the majority of pathogenic missense variants associated with this condition. It exhibits reduced transactivation ability (PMID: 11179011).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62beeb2e-75b9-448a-b021-af85c8a27d9d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This missense variant exhibits DNA binding approximately equivalent to the wild-type, but reduced transactivation ability in luciferase reporter assays (17.3% of wild-type, PMID: 11179011).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/62beeb2e-75b9-448a-b021-af85c8a27d9d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","allele":{"id":"https://genegraph.clinicalgenome.org/r/1e933f46-a0d6-4691-817a-8ff102ae706c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.378C>G (p.Ile126Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119634"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4758e077-92cb-4e9d-af08-ceaba4009957","type":"EvidenceLine","dc:description":"The apparently de novo origin of the variant and the severe defect in DNA binding are sufficient evidence for an impact on the function of the gene product.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4758e077-92cb-4e9d-af08-ceaba4009957_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001453.3(FOXC1):c.388C>T (p.Leu130Phe) is a missense variant located within the region of FOXC1 known to encode the Forkhead domain, which harbors the majority of pathogenic missense variants. The variant appears to trigger at least some reduction in nuclear localization (Figure 4), reduced transactivation ability to <40% of wild-type (Figure 6), and a severe defect in DNA binding (Figure 5).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4758e077-92cb-4e9d-af08-ceaba4009957_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17210863","allele":{"id":"https://genegraph.clinicalgenome.org/r/3149021f-1a2f-4b59-964f-11630ea24a8b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.388C>T (p.Leu130Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119643"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/235d19ae-faba-4b49-9d0c-9706479299dc","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.153_163del (p.His52fs) is a frameshift variant predicted to either trigger NMD or disrupt ~91% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/235d19ae-faba-4b49-9d0c-9706479299dc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","allele":{"id":"https://genegraph.clinicalgenome.org/r/815bb085-c82b-4cff-9309-1f2d45107360","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.153_163del (p.His52fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/8451"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1c76c4f0-4d76-46c0-9609-bc2fd85f9f12","type":"EvidenceLine","dc:description":"The variant exhibits a modest defect in transactivation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c76c4f0-4d76-46c0-9609-bc2fd85f9f12_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001453.3(FOXC1):c.245G>C (p.Ser82Thr) is a missense variant that exhibits a modest (3X to 5X) reduction in binding to its canonical DNA binding site in vitro (PMID: 11179011, Fig. 5A) and only weak affinity for oligonucleotides designed to mimic FOXC1 binding sites (Figs. 6B and 6C). Activation of a luciferase reporter construct was reduced to 56.9% of the wild-type (PMID: 11179011, Fig. 7). Although the variant occurs within the nuclear localization signal, its localization appears to be similar to wild-type (PMID: 11179011).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1c76c4f0-4d76-46c0-9609-bc2fd85f9f12_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9792859","allele":{"id":"https://genegraph.clinicalgenome.org/r/176dfa60-abca-444a-b397-d8afa33452bd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.245G>C (p.Ser82Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119639"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8624736-d42a-424a-8283-4595a65b584a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9792859","rdfs:label":"Mears_1998_IRID1_Family_3","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/f8624736-d42a-424a-8283-4595a65b584a","type":"Family","rdfs:label":"Mears_1998_IRID1_Family_3","member":{"id":"https://genegraph.clinicalgenome.org/r/effd49df-3e8e-4d5a-916c-945817172c6c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9792859","rdfs:label":"Mears_1998_IRID1_Family_3_Proband_III:1","allele":{"id":"https://genegraph.clinicalgenome.org/r/176dfa60-abca-444a-b397-d8afa33452bd"},"detectionMethod":"The patient was subjected to genotyping by PCR amplification of a region within the FOXC1 locus followed by restriction digest with the AluI enzyme, targeting a site abolished by the variant. Genotyping of the locus by Sanger sequencing of PCR products is also likely but not described.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Noted in the presentation of disease in at least some affected family members is HP:0000501 (Glaucoma).","phenotypes":["obo:HP_0009918","obo:HP_0007676","obo:HP_0000627"],"previousTesting":true,"previousTestingDescription":"Microsatellite-based linkage analysis, with highest linkage with the microsatellite marker D6S344 (chr 6p25) at a maximum recombination fraction of 0.00 (PMID: 9326342)","secondTestingMethod":"Restriction digest","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1c76c4f0-4d76-46c0-9609-bc2fd85f9f12_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Noted in the presentation of disease in at least some affected family members is HP:0000501 (Glaucoma).","phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0007676","obo:HP_0009918","obo:HP_0000627"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/effd49df-3e8e-4d5a-916c-945817172c6c"},"publishedLodScore":3.31,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/aee4d3d3-5f5c-4f13-b421-0a2c3a30d9ae_proband_segregation","type":"FamilyCosegregation","dc:description":"While individual affected family members were not all subjected to candidate gene sequencing, microsatellite-based linkage analysis found co-segregation of the locus with the condition.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10713890","rdfs:label":"Mirzayans_2000_Family_1","estimatedLodScore":2.41,"family":{"id":"https://genegraph.clinicalgenome.org/r/aee4d3d3-5f5c-4f13-b421-0a2c3a30d9ae","type":"Family","rdfs:label":"Mirzayans_2000_Family_1","member":{"id":"https://genegraph.clinicalgenome.org/r/23eaeb15-4117-4c20-ae74-dcbd4498198d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10713890","rdfs:label":"Mirzayans_2000_Family_1_Proband_I-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":60,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e870de00-c556-4b27-9f89-c6a85480853f"},"detectionMethod":"The proband was subjected to Sanger sequencing of the FOXC1 locus.","firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0007676","obo:HP_0011800","obo:HP_0000627","obo:HP_0007833","obo:HP_0010881","obo:HP_0000601","obo:HP_0000691"],"previousTesting":true,"previousTestingDescription":"Microsatellite-based linkage analysis was performed, linking the condition to chromosome 6p25 and excluding the PITX2 and RIEG2 loci previously implicated in similar conditions.\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/59847601-c8b7-4b29-a8f5-ec9e450611aa_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Noted in the presentation of disease in at least some affected family members are HP:0000501 (Glaucoma), HP:0011484 (Posterior synechiae of the anterior chamber), HP:0009917 (Persistent pupillary membrane), HP:0011800 (Midface retrusion), HP:0000691 (Microdontia), HP:0000601 (Hypotelorism), HP:0010881 (Abnormality of the umbilical cord), HP:0001627 (Abnormal heart morphology), and HP:0000365 (Hearing impairment)","phenotypePositiveAllelePositive":9,"phenotypes":["obo:HP_0007676","obo:HP_0000627"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/23eaeb15-4117-4c20-ae74-dcbd4498198d"},"publishedLodScore":2.71,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/95798822-3746-41dc-9cdb-fbc7fdf05549_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","rdfs:label":"Nishimura_1998_Family_4","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/95798822-3746-41dc-9cdb-fbc7fdf05549","type":"Family","rdfs:label":"Nishimura_1998_Family_4","member":{"id":"https://genegraph.clinicalgenome.org/r/abd346e0-0e4c-44f8-b85a-109213b6a301","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","rdfs:label":"Nishimura_1998_Family_4_Proband_IV:2","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f9f36c9-9056-48f1-91f9-cf604cc92982","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.335T>C (p.Phe112Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119636"}},"detectionMethod":"The patient was subjected to genotyping by PCR of exons from FOXC1, followed by Sanger sequencing.","firstTestingMethod":"SSCP","phenotypes":["obo:HP_0000558","obo:HP_0000659"],"previousTesting":true,"previousTestingDescription":"The affected proband was subjected to SSCP analysis of glaucoma-related genes such as CYP1B1 and PITX2, then subsequently to SSCP of the FOXC1 and GMDS loci (Figures 6 and 7).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e40b496d-c306-4647-960a-350d409d8efa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9620769","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f9f36c9-9056-48f1-91f9-cf604cc92982"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0007700","proband":{"id":"https://genegraph.clinicalgenome.org/r/abd346e0-0e4c-44f8-b85a-109213b6a301"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e40b496d-c306-4647-960a-350d409d8efa","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.335T>C (p.Phe112Ser) is a missense variant located within the forkhead (DNA-binding) domain, which harbors the majority of pathogenic missense variants associated with this condition. It exhibits reduced transactivation ability (PMID: 11179011).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e40b496d-c306-4647-960a-350d409d8efa_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant binds DNA at slightly enhanced levels (1X-2X relative to wild-type) but shows only 11.7% of wild-type transactivation ability in luciferase reporter assays (PMID: 11179011).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e40b496d-c306-4647-960a-350d409d8efa_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/30272e15-4f0d-4b7a-8f57-9341fa9e1c3e","type":"EvidenceLine","dc:description":"NM_001453.3(FOXC1):c.261C>G (p.Ile87Met) is a missense variant located within the region of FOXC1 known to encode the Forkhead domain, which harbors the majority of pathogenic missense variants.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/30272e15-4f0d-4b7a-8f57-9341fa9e1c3e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9792859","allele":{"id":"https://genegraph.clinicalgenome.org/r/213db2cd-29eb-4f8e-885a-e731d5b4fde9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001453.3(FOXC1):c.261C>G (p.Ile87Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119641"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7c827cb-f3f0-4dee-9bb2-eeb8c5cd4d61","type":"EvidenceLine","dc:description":"The model was scored at low levels due to the limited details regarding the ocular phenotype match to the human patients. On the other hand, the ocular vasculature phenotypes matched reports of corneal neovascularization from a mouse model and human patients (PMID: 22171010).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87c5873a-4fb3-441e-b674-aaa9f90be222","type":"Finding","dc:description":"Morpholino-based knockdown of foxC1a, the zebrafish ortholog of human FOXC1, triggered hydrocephaly, small eye, and hemorrhage primarily within the eyes and CNS (Figure 2A). This is consistent with the function of FOXC1 in regulating vascular growth (PMID: 22171010) and the proposed role of corneal neovascularization in the pathology of human patients harboring FOXC1 variants. Please note that this morpholino-based result has since been replicated / complemented by similar phenotypes in a zebrafish foxC1a knockout model (PMID: 32720677, Figures 1F-1I, 2F-2H, 3F-3J). Both models are poor matches for the autosomal dominant mode of inheritance from the human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19458328","rdfs:label":"Zebrafish knockdown of foxC1a","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3571555c-662f-420f-99bf-8c972dfc7f43","type":"EvidenceLine","dc:description":"Scoring was reduced to reflect the fact that this curation has already scored similar ocular phenotypes in another mouse model with disruption of Foxc1 (PMID: 22171010).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/50eaf2f9-66a5-44f2-8c61-f0bb8bc0536a","type":"Finding","dc:description":"The mouse closely recapitulates the ocular phenotypes of the human patient, ranging from Ectopia pupillae and Anterior embryotoxon to abnormal irido-corneal attachments, hypoplastic iris stroma, and abnormalities in Schlemm's canal and trabecular meshwork. The mouse also matched the mode of inheritance from the human condition.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10767326","rdfs:label":"Heterozygous mouse knockout of Foxc1","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c4dd5897-7f2e-431c-b0e9-0d4de8e9c19c","type":"EvidenceLine","dc:description":"The mouse model did not introduce a Foxc1 variant similar to those harbored in human patients, but rather harbored a previously described null mutation (PMID: 9635428). The presence of human patient-like phenotypes with a shared mode of inheritance supports the conclusions that the human condition results from loss of FOXC1 function.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b589d6c6-f3df-4340-acff-0fa187c3da1e","type":"Finding","dc:description":"5 out of 11 mice harboring heterozygous null disruption of Foxc1 in the neural crest lineage exhibited abnormal shape and/or positioning of the pupils at age 11 weeks (Figure 2A). Homozygous mice exhibited additional defects in corneal ultrastructure, but were not considered as they did not match the mode of inheritance of the human patients. While corneal neovascularization in heterozygous animals was not as drastic as in their homozygous counterparts, sprouting of limbal blood vessels and lymphatic vessels was significantly enhanced in heterozygous mice relative to wild-type controls (Figure 3C). The enhancement of blood vessel and lymphatic vessel sprouting induced by corneal alkali burn injury was also enhanced in heterozygous animals relative to the wild-type (Figure 5B).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22171010","rdfs:label":"Heterozygous mouse knockout of Foxc1 in neural crest cells","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b48f36b-6571-42a2-ad7d-1cf471f79a6b","type":"EvidenceLine","dc:description":"Multiple variants show loss of transactivation, matching results from a previous publication (PMID: 11179011).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47b55b14-ff78-4725-96fe-add7909097ee","type":"FunctionalAlteration","dc:description":"All five variants disrupt transactivation by FOXC1, reducing activity to 15-50% of wild-type according to luciferase reporter assay (Figure 2, matching results from a previous publication, PMID: 11179011). All five variants also increase cytoplasmic localization of this normally-nuclear protein by 29-82% (Table 2). However, previously characterized missense variants did not share this latter property.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14506133","rdfs:label":"Functional analysis of FOXC1 missense variants"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b2271229-84ea-4aff-81b4-3428c173ed7b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41bdb04f-baf2-43dc-9fbe-2d69db6d1c78","type":"EvidenceLine","dc:description":"FOXC1 functions as a transcription factor in trabecular meshwork cells to activate gene expression programs that protect against oxidative stress.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1caa97ee-d9be-4e88-8306-373e7c345c01","type":"Finding","dc:description":"The ChIP / HSPA6 data help to link FOXC1 to the ability of trabecular meshwork cells to respond severe oxidative stress. This connection between FOXC1 and trabecular meshwork cell survival represents a potential connection between patients harboring FOXC1 loss-of-function variants and the development of glaucoma. Overall, the transcription factor function of FOXC1 (PMID: 11782474) helps explain the findings that some variants compromise nuclear localization, DNA binding, and/or transactivation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24556684","rdfs:label":"FOXC1 chromatin IP from trabecular meshwork cells","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b72f556e-2437-4ce2-a495-e9d401efb938","type":"EvidenceLine","dc:description":"FOXC1 and PITX2 are transcription factors that physically interact in vitro and co-localize in vivo.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00842bf2-acee-43b4-ab08-be63c966e9d2","type":"Finding","dc:description":"Co-immunoprecipitation of the exogenously expressed proteins from transfected COS7 cells can be found in Figure 3. Affinity chromatography-based pull-down experiments showing that immobilization of one purified protein as bait can successfully pull down the other from cell extracts can be found in Figure 4. Co-localization experiments detecting both proteins by immunofluorescence in similar domains within the cell nucleus can be found in Figure 6.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16449236","rdfs:label":"FOXC1 physical interaction and colocalization with PITX2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":3785,"specifiedBy":"GeneValidityCriteria8","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cZc8s2Z_P94","type":"GeneValidityProposition","disease":"obo:MONDO_0024456","gene":"hgnc:3800","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_b2271229-84ea-4aff-81b4-3428c173ed7b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}